We partner with pharmaceutical companies to advance their therapeutic assets using the MeticTouch® non-invasive delivery platform. We are structured as an asset-light, technology-enabling company.
License the MeticTouch® platform for use with your proprietary therapeutic assets. Structured as upfront, milestone-based, and royalty payments.
Structured feasibility study to validate MeticTouch® compatibility with your compound before committing to a full licensing agreement.
Joint development of MeticTouch® for a specific therapeutic asset, with shared IP and co-commercialisation rights.
[TBD] Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation.
Yes. We have extensive experience providing feasibility evaluations in various formats, including on-site demonstrations at our facilities and collaborative studies conducted at a mutually agreed CRO. This is our preferred starting point for new partnerships.
We are happy to share a summary of our preclinical data package — covering efficacy, PK, and safety findings — prior to CDA execution. Detailed study protocols, full reports, and raw experimental data are available under a signed NDA.
We have validated compatibility with Aflibercept (Eylea®), Ranibizumab (Lucentis®), and Bevacizumab (Avastin®). A large-molecule NHP efficacy study with Faricimab (Vabysmo®) is currently underway with results expected Q3 2026.
MeticTouch® is trial-ready: preclinical evaluation is complete, ISO 13485 quality management systems are in place, and clinical-grade units have been manufactured. We are targeting First-in-Human trial initiation in 2026.
The non-invasive transscleral pathway is a compelling alternative for large-molecule gene therapy delivery. We are actively seeking partners to explore this application. Please contact us to discuss.
Tell us about your molecule, indication, and partnership interest. Our business development team will follow up with next steps for data-pack access or a feasibility discussion.
